Entresto: Why Is There Silence? We're Not Selling iPhones

ACC Conference Reporter

ACC.16 | CHICAGO — More than 18 months after Milton Packer, MD, reported that Entresto (sacubitril/valsarta) reduced mortality in heart failure, and 8 months after the FDA approved the drug, guidelines have not been changed and physicians have been slow to prescribe it. Why? Read More >>>

Keywords: ACC Annual Scientific Session

< Back to Listings